Prostate cancer trials in Taiwan

In Taiwan 31 Also abroad 1481

31 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Kaohsiung City, Taichung, Taipei, Taoyuan
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Taichung, Tainan, Taoyuan
Age
18 years and over
People
800 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Kaohsiung City, Taichung, Taipei, Taiwan
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Where
Taipei
Age
18 years and over
People
205 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07288359
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Kaohsiung City, New Taipei City, Taipei, Taoyuan
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Taipei, Taoyuan
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Kaohsiung City, Taipei, Taoyuan
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Taichung, Taipei
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Liou Ying Township, Taipei, Taoyuan
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 2/3Taking people
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Where
Taipei, Taoyuan
Age
18 years to 100 years
People
443 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00
No phaseTaking people
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
Where
Taipei
Age
30 years to 100 years
People
360
Run by
National Taiwan University Hospital
See details and how to joinNCT03237026
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Kaohsiung City, Taichung, Taipei
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1Taking people
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Taipei, Taoyuan
Age
18 years and over
People
479 worldwide
Run by
Amgen
See details and how to joinNCT04221542 · EU 2023-504361-23-00
Phase 1Taking people
Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
Where
Taipei
Age
20 years and over
People
12
Run by
National Taiwan University Hospital
See details and how to joinNCT07621692
No phaseTaking people
Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
Where
Keelung, Taoyuan
Age
20 years to 90 years
People
60
Run by
National Taipei University of Nursing and Health Sciences
See details and how to joinNCT07196488